On March 3, 2021 Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, reported that company executives will participate in three investor conferences in March 2021 (Press release, Sierra Oncology, MAR 3, 2021, View Source [SID1234575987]). Stephen Dilly, MBBS, PhD, Chief Executive Officer of Sierra will provide a company update at the HC Wainwright Life Sciences Conference and the Oppenheimer Healthcare Conference; Barbara Klencke, MD, Chief Development Officer will participate in a panel discussion at the 33rd Annual Roth Conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:

Conference:

HC Wainwright Global Life Sciences Conference

Presenter:

Stephen Dilly, MBBS, PhD, Chief Executive Officer

Date:

Tuesday, March 9, 2021

Time:

On Demand Viewing starting at 7:00 am ET

Conference:

Virtual 33rd Annual Roth Conference

Presenter:

Barbara Klencke, MD, Chief Development Officer

Session:

Large Market Opportunities in RARE Hematologic & Inflammatory Disease

Date:

Monday, March 15, 2021

Time:

10:00 am – 11:00 am ET

Conference:

Oppenheimer 31st Annual Healthcare Conference

Presenter:

Stephen Dilly, MBBS, PhD, Chief Executive Officer

Date:

Wednesday, March 17, 2021

Time:

1:50 pm – 2:20 pm ET

All three presentations will be webcast and available at the times noted above on the Investors section of Sierra’s corporate website in the Events & Webcast tab.

On March 3, 2021 Oasmia Pharmaceutical AB, an innovation-focused specialty pharmaceutical company, reported that it has signed an agreement with the Karolinska Institutet, Stockholm, Sweden (Press release, Oasmia, MAR 3, 2021, View Source [SID1234575986]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The collaboration will generate new information aiming at the development of new therapeutic APIs. The XR-17 proprietary platform technology enhances intravenous delivery of established and novel drugs in diseases including cancer.

The collaboration will include a review of data and experimental methods to gain a deeper understanding of XR-17 and API formulations in cancer indications with a focus on ovarian carcinoma. This will be followed by an experimental planning phase, which aims to test formulations in suitable systems to generate hypotheses for subsequent evaluation.

Commenting on the collaboration, François Martelet, M.D., Chief Executive Officer of Oasmia, said: "XR-17’s potential to improve drug solubility has been demonstrated by the approval of Apealea for ovarian cancer in Europe, with a second investigational product preparing to enter clinical studies in Switzerland this year. We are delighted to be working with the Karolinska Institutet, one of the most prestigious medical universities and research centers in the world, to further develop our understanding of the potential of this technology in enhancing cancer treatment. Our collaboration with Prof. Rolf Lewensohn and his team at the Department of Oncology-Pathology may lead to the identification of additional applications for the technology and the development of new therapeutics to benefit cancer and other patients."

Prof. Rolf Lewensohn, Principal Investigator at the Karolinska Institutet, Department of Oncology-Pathology, said: "We are looking forward to working with Oasmia on this project. The knowledge and understanding we will be able to generate through this collaboration will help us to better understand the biological properties of XR-17 by defining plasma and target tissue behavior and receptor and transporter affinity. This important work could ultimately enable new study protocols to be drafted."

On March 3, 2021 Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, reported that Emil D. Kakkis, M.D., Ph.D., the company’s Chief Executive Officer and President, will present at the Barclays Global Healthcare Conference on Wednesday, March 10, 2021 at 4:45 PM ET (Press release, Ultragenyx Pharmaceutical, MAR 3, 2021, View Source [SID1234575985]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live and archived webcast of the presentation will be accessible from the company’s website at View Source The replay of the webcast will be available for 90 days.

On March 3, 2021 Cerus Corporation (Nasdaq: CERS) reported that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Kevin D. Green, Cerus’ chief financial officer, are scheduled to participate in the Jefferies Virtual Global Plasma Summit on Thursday, March 11, 2021 at 11:00 am PT/ 2:00 pm ET (Press release, Cerus, MAR 3, 2021, View Source [SID1234575984]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the events will be available on the Investor Relations page of the Cerus web site at View Source A replay will be available for approximately two weeks following the completion of the event.

On March 2, 2021 Keros Therapeutics, Inc. ("Keros") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, reported that Keros President and Chief Executive Officer Jasbir S. Seehra, Ph.D. will present at the H.C. Wainwright Global Life Sciences 2021 Virtual Conference (Press release, Keros Therapeutics, MAR 2, 2021, View Source [SID1234580476]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be available on Tuesday, March 9 starting at 7:00 am ET at View Source and archived in the Investors section of the Keros website at View Source A replay will be available for 90 days following the conclusion of the event.